Background: We assessed long-term cardiac safety and efficacy in patients with human epidermal growth factor receptor 2epositive early breast cancer treated with a trastuzumab biosimilar (SB3) or its reference product, trastuzumab (TRZ), in a phase 3 study. Methods: Patients who completed the phase 3 study could be enrolled in this extension study. The outcomes included the incidence of symptomatic congestive heart failure (CHF), asymptomatic significant left ventricular ejection fraction (LVEF) decrease, incidence of other cardiac events, event-free survival (EFS), and overall survival. In post hoc analysis, the Cox proportional hazards regression model was used to assess factors associated with EFS. Results: A total of 367 patients were enrolled in the study (SB3, n Z 186; TRZ, n Z 181). The median follow-up duration from the main study enrolment was 40.8 and 40.5 months for SB3 and TRZ, respectively. During the two-year follow-up after adjuvant therapy, incidence of asymptomatic significant LVEF decrease was rare (SB3, n Z 1; TRZ, n Z 2), with all patients

Silver nanowires whose diameters could be controlled in the range of 15–30 nm and lengths up to ∼20 μm were prepared by the high-pressure polyol method. The first step involved the formation of Ag nanoparticles by reducing silver nitrate in the presence of NaCl and KBr with ethylene glycol. At the growing step, the adjustable reaction pressure controls the diameter of the silver nanowires, which were in the range 15–22 nm when the pressure was 200 psi. These Ag nanowires showed an electrical conductivity of 0.4 × 105 S/cm, and the intensity of scattered light and the optical transmittance were largely improved.

Novel mixed amido-/imido-/guanidinato-complexes of tantalum are reported. The complexes were synthesised by insertion reactions of carbodiimides of the type C(NR)2(R =iso-propyl (i-Pr)) into the M-N bonds of tantalum mixed amido/imido complexes. Three representative complexes were synthesised and fully characterised by 1H-NMR, 13C-NMR, CHN-analysis and mass spectroscopy. The crystal structure of the complex [Ta(NMe2){(i-Pr-N)2C(NMe2)}2(N-t-Bu)](1)(Me = methyl, t-Bu =tert-butyl) is presented and discussed. The complexes are solids that can be quantitatively sublimed at moderate temperatures (120-130 degrees C) without any sign of decomposition. The thermal properties of the new compounds were studied (TGA) and preliminary MOCVD-experiments were performed. TaN films were deposited and characterised by XRD and XPS.

No abstract

No abstract